Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial.

@article{Mavroudis2000FrontlineTO,
  title={Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial.},
  author={Dimitrios Mavroudis and C H Kourousis and Nikolaos E Androulakis and Kostas Kalbakis and Sohia Agelaki and Stylianos Souglakos John Kakolyris and John Souglakos and Evanthia Sarra and Nikolaos Vardakis and Dora Hatzidaki and G Sarmonis and Vassilis Georgoulias},
  journal={American journal of clinical oncology},
  year={2000},
  volume={23 4},
  pages={341-4}
}
We conducted a phase II study to evaluate the efficacy and tolerance of docetaxel monotherapy with granulocyte colony-stimulating factor (G-CSF) support in patients with advanced gastric cancer. Thirty patients with measurable advanced gastric cancer were enrolled. Twenty-four patients were chemotherapy-naive and six patients had previously received adjuvant chemotherapy after complete surgical resection. Docetaxel was administered at 100 mg/m2 IV during 1 hour every 3 weeks. G-CSF 5 microg/kg… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 40 extracted citations

Review of docetaxel in the treatment of gastric cancer

Therapeutics and clinical risk management • 2008
View 1 Excerpt
Highly Influenced

Similar Papers

Loading similar papers…